Enabling Cutting-Edge Technologies That Will Help Shape Our Future

​2123 Frontiers uses our research, experts, and gatherings to take a systems approach to “enable” current cutting-edge technologies in science, engineering, medicine and technology.

Defining a frontier or breakthrough is no easy feat, but at its core, we believe these are “significant” advancements with the potential to create a positive impact on humanity. Honestly, some of them will work, and many may not. Some will be quick; some will take decades. The most important thing is to have the aspiration to change the trajectory of societal impact.

We believe this magic happens at the intersection of science, medicine, business, and engineering, driven by leaders who have the boldness, resilience, and persistence to push the envelope on new frontiers and drive breakthroughs!! Our platform brings together driven entrepreneurs, innovators, pioneers, and visionaries, all with a common purpose — “enabling” breakthroughs as we collectively push society’s frontiers.

Our Frontiers

Healthcare & Life Sciences

The pace of medical innovation continues to accelerate with new ideas being pursued. Scientists are focused on several major areas of unmet need from rare diseases (Huntington’s disease, sickle cell anemia) to neurological conditions (Alzheimer's, Parkinson's, Epilepsy) to oncology (pancreatic cancer, lung cancer, colorectal cancer) and metabolic health (diabetes, obesity, hormonal conditions).

Scientists have been making significant progress on many new tools and foundational capabilities e.g. gene editing, pharmacogenomics, personalized medicine, predictive analysis, novel biomarkers, implantable/wearable devices, tissue cell engineering. These new diagnostics, devices, drugs, and software/AI will allow us to better tackle some of the most impactful diseases in medicine.

We want to enable innovators, scientists, physicians, investors and entrepreneurs to accelerate the pace of medical innovation for humanity.

High Tech

Solutions that improve data structure, data architecture models, and data related technologies such as generative AI, large language models, cloud-native data, real time data processing are foundational.

Advancement in computation such as hardware advancement (quantum computing, semiconductors), software, and algorithms (high performance computing, quantum algorithms) are enabling the processing of larger amounts of data.

Spatial computing, Augmented reality (AR), Virtual reality (VR) and mixed reality is considered the next big paradigm shift in computing, enabling human-computer interaction to take place in the real world, in and around natural bodies and physical environments.

Innovations in robotics such as soft robotics, autonomous systems, human-robot interactions, bio-inspired robotics and AI and robotics integration have wide-ranging applications in a variety of industries such as healthcare, manufacturing, education.

To enable the secure implementation of technology, advances in cybersecurity tools such as zero trust architecture, next generation cloud workforce protection, password-less authentication, blockchain, quantum computing as well as ethical and legal guidelines must be put into place.

All these innovations will contribute to transformation in every industry and bringing us closer to a reality once only imagined!

Company Spotlight: Senticell™

Overview: Senticell™ is a biotechnology and molecular diagnostics company pioneering a breakthrough liquid biopsy platform based on red blood cell (RBC) associated nucleic acids.  Guided by their vision, “One Cell. Your Future,” they are dedicated to enabling earlier disease detection, biologically enriched biomarker discovery, using existing diagnostic workflows.

Key Highlights Include:

  • A New Biological Starting Point: Senticell is built on more than 15 years of research demonstrating that RBCs are active immune sensors that bind circulating DNA.

  • Superior Signal Detection: Their platform is designed to enhance biological signal detection in low-burden diseases where sensitivity directly impacts treatment decisions such as oncology and infectious disease.

  • Unique Value Proposition: The Senticell Signal Reservoir platform offers exponentially higher signal detection, PCR-compatible workflows (rapid and cost-effective), < 24-hour turnaround time and improved sensitivity.

Leadership: Neha Shah, MBA (CEO), Mallik Srivatsan, PhD, MBA (COO) and Nilam Mangalmurti, MD (Chief Scientific Advisor).

Financials: Previously closed a $5M seed round in February 2026, led by Venture City and Capital Factory, now preparing to raise $20M Series A round in Summer 2026 to fund CLIA lab buildout and assay development.

Upcoming Milestones:

  • First revenues expected: 2027

  • CLIA commercial launch in MRD and driver mutations in HPV-driven cancers (Head & Neck and cervical) and oncogenic driver mutation cancers (lung and pancreatic cancer): 2028

  • Scale through biopharma collaborations and diagnostic platform partnerships.

Login to Access Content

2123 Frontiers Salon

An engaging evening of conversation, connection, advise shared over some amazing updates from the Biotech featured on the 2123 Frontiers platform, Reverb Therapeutics, Neuropeutics Inc, Aveta Biomics Inc and Switchback Therapeutics.